Now, later or never? Challenges associated with hepatitis C treatment

McNally, Steve; Temple-Smith, Meredith; Sievert, William; Pitts, Marian

doi:10.1111/j.1467-842x.2006.tb00457.x

Cited by 31 publications

(27 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…McNally et al [8] proposed that confidence in treatment efficacy was the main consideration in deciding to undertake treatment. Underscoring the contextual influences involved in making treatment decisions, Ogawa and Bova [73] suggested that treatment decisions in former IDU were complicated by fears that self injecting interferon could reintroduce the use of syringes in a way that might threaten their control over their injecting drug use.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The ongoing impacts of hepatitis c - a systematic narrative review of the literature

et al. 2012

View full text Add to dashboard Cite

BackgroundMany countries have developed, or are developing, national strategies aimed at reducing the harms associated with hepatitis C infection. Making these strategies relevant to the vast majority of those affected by hepatitis C requires a more complete understanding of the short and longer term impacts of infection. We used a systematic approach to scope the literature to determine what is currently known about the health and psychosocial impacts of hepatitis C along the trajectory from exposure to ongoing chronic infection, and to identify what knowledge gaps remain.MethodsPubMed, Current Contents and PsychINFO databases were searched for primary studies published in the ten years from 2000–2009 inclusive. Two searches were conducted for studies on hepatitis C in adult persons focusing on: outcomes over time (primarily cohort and other prospective designs); and the personal and psychosocial impacts of chronic infection. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness and methodological coherence. Outcomes reported in 264 included studies were summarized, tabulated and synthesized.ResultsInjecting drug use (IDU) was a major risk for transmission with seroconversion occurring relatively early in injecting careers. Persistent hepatitis C viraemia, increasing age and excessive alcohol consumption independently predicted disease progression. While interferon based therapies reduced quality of life during treatment, improvements on baseline quality of life was achieved post treatment – particularly when sustained viral response was achieved. Much of the negative social impact of chronic infection was due to the association of infection with IDU and inflated assessments of transmission risks. Perceived discrimination was commonly reported in health care settings, potentially impeding health care access. Perceptions of stigma and experiences of discrimination also had direct negative impacts on wellbeing and social functioning.ConclusionsHepatitis C and its management continue to have profound and ongoing impacts on health and social well being. Biomedical studies provided prospective information on clinical aspects of infection, while the broader social and psychological studies presented comprehensive information on seminal experiences (such as diagnosis and disclosure). Increasing the focus on combined methodological approaches could enhance understanding about the health and social impacts of hepatitis C along the life course.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Between 70% and 85% of those initially infected fail to clear the virus [5-7]. Hepatitis C treatments are available, but uptake remains low even in countries such as Australia, where treatment is available at low cost to eligible patients [8,9]. Thus, most people with hepatitis C infection face the prospect of lifelong chronic infection.…”

Section: Introductionmentioning

confidence: 99%

The ongoing impacts of hepatitis c - a systematic narrative review of the literature

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This finding is consistent with female, HCV mono-infected patients declining therapy significantly more often than their male counterparts (Khokhar & Lewis, 2006). Similarly, men were found to be twice as likely to be treated for HCV as women (McNally, Temple-Smith, Sievert, & Pitts, 2006). The reasons why women decline HCV treatment more often than men is unclear and requires further investigation.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection

Bova¹,

Ogawa²,

Sullivan-Bolyai³

2010

Journal of the Association of Nurses in AIDS Care

View full text Add to dashboard Cite

Hepatitis C Treatment Experiences and Decision-Making Among Patients Living with HIV InfectionAbstract Hepatitis C infection is a major problem for approximately 250,000 HIV-infected persons in the United States. Although HIV infection is well controlled in most of this population, they suffer liver-associated morbidity and mortality. Conversely, HCV treatment uptake remains quite low (15-30%). Therefore, the purpose of this qualitative study was to explore HCV treatment experiences and decision-making in adults with HIV infection. The study sample included 39 co-infected adults, 16 in the HCV-treated cohort (who were interviewed up to 3 times) and 23 in the HCV-non-treatment cohort. Analysis of interviews identified 2 treatment barriers (fears and vicarious experiences) and 4 facilitating factors (experience with illness management, patient-provider relationships, gaining sober time, and facing treatment head on). Analysis of these data also revealed a preliminary model to guide intervention development and theoretical perspectives. Ultimately, research is urgently needed to test interventions that improve HCV evaluation and treatment uptake among HIV-infected patients. Keywordsdecision-making; Hepatitis C; HIV Treatment of HIV-infected persons with combination antiretroviral therapy (ART) in the past decade has altered the spectrum of liver disease. Liver abnormalities in this population are now less commonly due to opportunistic infections and neoplasm; the most prevalent liverassociated problem is hepatitis C virus (HCV; Bica et al., 2001;Sulkowski, Moore, Mehta, & Chaisson, 2002). The proportion of liver-related deaths among HIV-infected adults in the United States has increased 3-to 4-fold (Selik, Byers, & Dworkin, 2002). Even more striking, more than half (54.6%) of those HIV-infected patients who died of liver-related causes Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. HIV and HCV infections interact biologically. HIV infection is associated with higher HCV RNA levels and a more rapid progression of HCV-related liver disease (Zylberger & Pol, 1996). In a paired biopsy study, HIV infection was found to accelerate the rate of fibrosis progression by 1.4-fold and the development of advanced fibrosis 3-fold (Mohsen et al., 2003). Severity of liver fibrosis is also related to HIV infection-induced CD4 cell depletion (Puoti et al., 2001). A low CD4 cell count was independently associated with advanced HCV disease and correlated with a higher histological index (Mohsen et al., 2003). Therefore, in patients infected only with HCV, the time between infection an...

show abstract

“…These numbers are small because of the numerous deterrents to HCV treatment, which include side effects, the rigorous nature of treatment, and the impact of treatment on work and family (Doab et al, 2005; McNally et al, 2006; Wilson et al, 2010). Additionally, people with HCV may face competing health and social concerns that impede their access to care and treatment, including poverty (Edlin et al, 2005; McNally et al, 2006), unemployment, lack of stable housing (Edlin et al, 2005; Grebely et al, 2008) and comorbidity such as mental health problems (Weiss et al, 2012). Given the social and economic disadvantages experienced by Aboriginal Australians, these barriers could be exacerbated (Hunter, 2007).…”

Section: Introductionmentioning

confidence: 99%

The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis

Brener

Wilson

Jackson

et al. 2015

Health Psychology Open

View full text Add to dashboard Cite

This research assessed whether greater attachment to an Aboriginal community buffers against the negative effects of stigma and promotes positive health outcomes. Aboriginal Australians (n = 203) living with hepatitis C completed a survey assessing community attachment, stigma, resilience, quality of life, treatment intent, hepatitis C knowledge and positive lifestyle changes. A stronger sense of community attachment was associated with greater resilience, increased quality of life, less hepatitis C–related stigma and with increased lifestyle changes after diagnosis. Hence, community attachment can buffer against the negative health effects of stigma and may promote the resources to engage in positive behaviour changes, ultimately increasing long-term health outcomes.

show abstract

Now, later or never? Challenges associated with hepatitis C treatment

Abstract: Results:The average age of the

Cited by 31 publications

References 9 publications

The ongoing impacts of hepatitis c - a systematic narrative review of the literature

The ongoing impacts of hepatitis c - a systematic narrative review of the literature

Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection

The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis

Contact Info

Product

Resources

About